<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04740021</url>
  </required_header>
  <id_info>
    <org_study_id>LP002-II-SCLC-01</org_study_id>
    <nct_id>NCT04740021</nct_id>
  </id_info>
  <brief_title>Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer</brief_title>
  <official_title>A Single-arm, Open-lable, Multicenter, Phase II Clinical Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taizhou HoudeAoke Biomedical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taizhou HoudeAoke Biomedical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      LP002 is a highly selected recombinant humanized anti-PD-L1 monoclonal antibody. This is a&#xD;
      single-arm, multicenter study to evaluate the efficacy and safety of LP002 in combination&#xD;
      with chemotherapy in patients with extensive stage samll cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to approximately 15 months</time_frame>
    <description>PFS was defined as the time from randomization to the first documented disease progression per RECIST 1.1 assessed by investigators or death due to any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to approximately 15 months</time_frame>
    <description>ORR was defined as the percentage of participants who have a complete response (CR) or a partial response (PR), per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>up to approximately 15 months</time_frame>
    <description>DCR was defined as the percentage of participants who have a CR or a PR or a stable disease (SD), per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to approximately 15 months</time_frame>
    <description>DOR was defined as the time from the first documented evidence of a response of CR or PR, per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced an Adverse Event (AE)</measure>
    <time_frame>up to approximately 15 months</time_frame>
    <description>An adverse event was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have had a causal relationship with this treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Small-cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental: LP002+EP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants recieve LP002 10 mg/kg intravenous (IV) on day 1 PLUS carboplatin titrated to an area under the plasma drug concentration-time curve [AUC] 5 IV on day 1 PLUS etoposide 100 mg/m^2 IV on days 1, 2 and 3 of each 21-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LP002</intervention_name>
    <description>10 mg/kg administered as IV infusion on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Experimental: LP002+EP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC 5 administered as IV infusion on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Experimental: LP002+EP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>100 mg/m^2 administered as IV infusion on Day 1, 2 and 3 of each 21-day cycle.</description>
    <arm_group_label>Experimental: LP002+EP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be willing and able to provide written informed consent for the trial;&#xD;
&#xD;
          -  Age ≥ 18 and ≤ 79 years old, male or female;&#xD;
&#xD;
          -  Histologically or cytologically diagnosed with ES-SCLC (according to the Veterans&#xD;
             Administration Lung Study Group staging system).&#xD;
&#xD;
          -  No prior systemic therapy for ES-SCLC.&#xD;
&#xD;
          -  Patients who have received prior chemoradiotherapy for limited-stage SCLC must have&#xD;
             been treated with curative intent and experienced a treatment-free interval of at&#xD;
             least 6 months since last chemotherapy, radiotherapy, or chemoradiotherapy cycle from&#xD;
             diagnosis of extensive-stage SCLC.&#xD;
&#xD;
          -  Has Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1&#xD;
&#xD;
          -  Has a life expectancy of ≥3 months.&#xD;
&#xD;
          -  Has at least one measurable lesion based on Response Evaluation Criteria in Solid&#xD;
             Tumors (RECIST) version 1.1.&#xD;
&#xD;
          -  Has adequate organ function.&#xD;
&#xD;
          -  Female participants of childbearing potential should have a negative pregnancy within&#xD;
             72 hours before the first dose of trial treatment. Male and female participants should&#xD;
             agree to use an adequate method of contraception during the experiment and 24 weeks&#xD;
             after the last administration of the test drugs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed mixed SCLC.&#xD;
&#xD;
          -  Suffered from other malignant tumors in the past 5 years (except skin basal cell&#xD;
             carcinoma, squamous cell carcinoma, and cervical carcinoma in situ that have been&#xD;
             effectively controlled).&#xD;
&#xD;
          -  Prior to the first administration of the study drug, there was a grade &gt; 1 toxicity&#xD;
             (excluding hair loss) caused by previous anti-tumor treatments.&#xD;
&#xD;
          -  Has received prior therapy with an anti-PD-1, or anti-PD-L1, or anti-CTLA-4 agents.&#xD;
&#xD;
          -  Has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis.&#xD;
&#xD;
          -  Has uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated&#xD;
             drainage.&#xD;
&#xD;
          -  Uncontrolled or symptomatic hypercalcemia.&#xD;
&#xD;
          -  Spinal cord compression not definitively treated with surgery and/or radiation or&#xD;
             previously diagnosed and treated spinal cord compression without evidence that disease&#xD;
             has been clinically stable for ≤ 1 week prior to the first dose of trial treatment.&#xD;
&#xD;
          -  Has active autoimmune disease that has required systemic treatment in past 2 years.&#xD;
&#xD;
          -  Has received a major surgery within 4 weeks prior to the first dose of trial&#xD;
             treatment.&#xD;
&#xD;
          -  Has received system treatment with corticosteroids (dose &gt;10mg/day prednison or other&#xD;
             therapeutic hormones) within 2 weeks prior to the first dose of trial treatment.&#xD;
&#xD;
          -  Previous or present interstitial lung disease or non-communicable pneumonia, except&#xD;
             for radiation pneumonia.&#xD;
&#xD;
          -  Has uncontrolled systemic disease, such as diabetes or hypertension.&#xD;
&#xD;
          -  Has a history of testing positive for human immunodeficiency virus (HIV), or known&#xD;
             acquired immunodeficiency syndrome (AIDS), or stem cell transplantation or organ&#xD;
             transplantation.&#xD;
&#xD;
          -  Has untreated chronic hepatitis B or chronic hepatitis B virus (HBV) DNA exceeding 500&#xD;
             IU/ mL or active hepatitis C virus (HCV). Subjects with non-active HBsAg carriers,&#xD;
             treated and stable hepatitis B (HBV DNA &lt; 10^3 copies/ml or &lt;500 IU/ mL) , and cured&#xD;
             hepatitis C can be enrolled. Subjects with positive HCV antibodies are eligible only&#xD;
             if the HCV RNA test results are negative.&#xD;
&#xD;
          -  Has serious infections within 4 weeks or active infections requiring systemic&#xD;
             treatment within 2 weeks prior to the first dose of trial treatment.&#xD;
&#xD;
          -  Has a history of severe allergic reaction to any other monoclonal antibodies.&#xD;
&#xD;
          -  Has participated in other anticancer drug clinical trials within 4 weeks.&#xD;
&#xD;
          -  Is pregnant or breastfeeding.&#xD;
&#xD;
          -  Has received a live vaccine within 30 days prior to the first dose of trial treatment.&#xD;
&#xD;
          -  According to the judgement of the investigators, there are other factors that may lead&#xD;
             to the termination of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jialei Wang</last_name>
    <phone>021-64175590</phone>
    <email>wangjialeigcp@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huijuan Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lin Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital Of Jiangnan University</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214122</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaosheng Hang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Jinzhou Medical University</name>
      <address>
        <city>Jinzhou</city>
        <state>Liaoning</state>
        <zip>121000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhitu Zhu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shandong Cancer Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhifang Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jialei Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinjiang Medical University Cancer Center</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhigang Han</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yunnan Cancer Hospital</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Runxiang Liang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 1, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

